Aims/hypothesis We hypothesised that type 1 diabetic patients with established diabetic sensorimotor polyneuropathy (DSPN) would have segmental and/or pan-enteric dysmotility in comparison to healthy age-matched controls. We aimed to investigate the co-relationships between gastrointestinal function, degree of DSPN and clinical symptoms. Patients also showed an increased fall in pH across the ileocaecal junction (−1.8 ± 0.4 vs −1.3 ± 0.4 pH; p < 0.0001), which was associated with prolonged colonic transit (r = 0.3, p = 0.001). Multivariable regression, controlling for sex, disease duration and glycaemic control, demonstrated an association between whole-gut transit time and total GCSI (p = 0.02). Conclusions/interpretation Pan-enteric prolongation of gastrointestinal transit times and a more acidic caecal pH, which may represent heightened caecal fermentation, are present in patients with type 1 diabetes. The potential implication of delayed gastrointestinal transit on the bioavailability of nutrition and on pharmacotherapeutic and glycaemic control warrants further investigation. Trial registration EUDRA CT: 2013-004375-12 
Introduction
Type 1 diabetes is associated with microvascular disturbances leading to neuropathy in up to 50% of patients [1] . Diabetic peripheral neuropathy consists of two separate entities-diabetic sensorimotor polyneuropathy (DSPN) and diabetic autonomic neuropathy (DAN) [1] -which may or may not coexist in individual patients [2] . Classically, DSPN affects sensory and motor neurons in a 'stocking and glove' pattern, whereas DAN affects the cardiovascular, urogenital, sudomotor and gastrointestinal systems [1, 3] . Within the gastrointestinal tract, this may lead to sensorimotor aberrations, and symptoms such as nausea, vomiting, bloating, early satiety, distension and abdominal pain are frequently encountered [4] [5] [6] [7] .
Although the most frequently identified gastrointestinal complication of diabetes is gastroparesis [8] , which can itself exert a negative impact on the patient's glycaemic control and quality of life, gastrointestinal manifestations remain underrecognised [9] . Over a 10-year period, the cumulative HR for developing gastroparesis, relative to healthy controls, is 33 (95% CI 2, 274) in patients with type 1 diabetes in contrast to 7.5 (95% CI 0.8, 68) in those with type 2 diabetes [10] . Evidence suggests that the societal, economic and healthcare burden of gastroparesis is rising, arguably as a consequence of heightened clinical suspicion and improved access to diagnostics [11] . Given that gastroparesis represents a diminution in foregut motility, it can result in an unpredictable delivery of nutrients and medication from the stomach into the small bowel, which can adversely affect nutritional status, efficacy of medical treatment and glycaemic control [12] . Considering that the gastrointestinal tract is a continuous organ from mouth to anus, it is plausible to suggest that gastrointestinal dysmotility in type 1 diabetes is not purely confined to the foregut and that symptoms originating in one part of the gut may overlap with those in another. Localisation of any dysfunction is now recognised as a crucial first step for accurate diagnosis and further management [13, 14] .
Contemporaneous assessment of motility throughout the gastrointestinal tract generally utilises regional or pan-enteric scintigraphic evaluation. Such methods are, however, timeconsuming and necessitate exposure to radiation. The wireless motility capsule (WMC) is a novel validated method that measures regional and whole-gut transit times (WGTTs) in a noninvasive ambulatory manner within a single test [15] . The WMC consists of an indigestible single-use polyurethane capsule that measures pressure, pH and temperature as it traverses the gastrointestinal tract. Regional transit times are derived from stereotypical changes in gut pH. The magnitude of change in pH around the ileocaecal junction (ICJ) has recently been proposed as an objective surrogate biomarker of caecal fermentation, reflecting changes in the microbiota [16, 17] . We therefore hypothesised that a proportion of patients with type 1 diabetes and proven DSPN have gastrointestinal dysmotility, and we questioned whether any dysmotility identified would be regional or pan-enteric. We aimed to describe any differences between patients and healthy controls in terms of both regional and total transit times and ileocaecal pH patterns. Furthermore, we wanted to investigate the relationship between these findings and self-reported gastrointestinal symptoms and quality of life, as well as objective markers of DSPN.
Methods

Study population
The study comprised an observational comparison involving 48 consecutive patients with type 1 diabetes and verified DSPN (39 men, mean age 50 years, range 29-71 years), representing a secondary analysis of baseline data collected from an ongoing double-blind randomised controlled trial investigating the neuroprotective effects of liraglutide (Treatment of Diabetic Neuropathy With Liraglutide [TODINELI] trial; EUDRA CT 2013-004375-12). Patients were recruited at the Department of Endocrinology, Aalborg University Hospital, Denmark. Potential eligible patients were pre-screened on the basis of a recorded vibration perception threshold of over 18 V, and DSPN was verified by nerve conduction tests. No patients had a history of osteoporosis. Additional inclusion criteria were age over 18 years and a verified diagnosis of type 1 diabetes for a minimum of 2 years (HbA 1c ≥6.5% [>48 mmol/mol]). Patients' characteristics are listed in Table 1 . These patients were compared with 41 age-matched healthy participants from an established normal dataset (16 men, mean age 49 years, range 30-78 years) [15] . All healthy participants had a normal bowel habit, defined as between three bowel movements per day and one bowel movement every 3 days, with no gastrointestinal symptoms that were particularly suggestive of either small intestinal bacterial overgrowth (SIBO) or a rectal evacuatory disorder. No healthy participants had any gastrointestinal symptoms or history of metabolic, neurogenic or endocrine disorder known to influence gastrointestinal motor activity. In addition, no participant had undergone gastrointestinal surgery, other than appendectomy and/or cholecystectomy, and none was taking either laxatives or medications known to influence gastrointestinal motility or pH.
Protocol
Prior to entry into the study, all participants gave written informed consent. Patients underwent testing of peripheral nerve and autonomic nervous system function and completed a number of validated questionnaires prior to ingesting a WMC. Serum blood glucose concentrations were measured directly before participants ingested the WMC. Healthy participants only underwent WMC investigation and had a full history and clinical examination performed to confirm the absence of any exclusion criteria. All patient protocols were approved by the Ethics Committee for North Jutland, Denmark (EUDRA CT 2013-004375-12, Local ethical committee N-20130077).
Peripheral nerve function testing
Vibration perception threshold The threshold for vibratory perception was measured using a biothesiometer (BioMedical Instruments, Newbury, OH, USA), with the amplitude of the vibrations indicated by a voltmeter. The highest recordable value was 50 V. The vibrator was hand-held and applied to the dorsum of the first phalanx of each foot. The stimulus strength was increased gradually from zero to first sensation, and the test was repeated twice on both feet. The average was derived as the vibration perception threshold on each foot. Data are expressed as mean and SD unless otherwise stated a R-R interval: the time between successive R waves on the ECG b Calcium levels were not part of the study protocol; therefore these values represent the most recent values in the medical record RMSSD, root mean square differences of successive R-R intervals; SDANN, SD of sequential 5 min R-R interval means; SDNN, SD of normal-to-normal R-R intervals; SDNNi, mean of SDs of all normal-to-normal intervals in all 5 min segments of the ECG recording
Peripheral nerve conduction test The median, ulnar, sural, radial, tibial and peroneal nerves were evaluated, including sensory and motor components. However, for this study, only the results for sensory median nerve testing are included. To avoid temperature influencing the conduction velocity, appropriate warming measures were used to ensure that skin temperatures were at least 32°C. Spring-ring electrodes were used for recording digital sensory nerve action potentials. For all other nerves, a plastic bar electrode was used.
Heart rate variability
All patients undertook a 24-h ECG recording from which heart rate variability (HRV) indices were derived (for further details, see the electronic supplementary material [ESM]).
Questionnaires
Michigan Neuropathy Screening Instrument The validated Michigan Neuropathy Screening Instrument (MNSI) was administered to screen for DSPN. A score of >7 is considered abnormal.
PAGI-SYM questionnaire Gastrointestinal symptoms in the preceding 2 weeks were assessed using the Patient Assessment of Gastrointestinal Disorder Severity (PAGI-SYM), from which the Gastroparesis Cardinal Symptom Index (GCSI) was derived. (See ESM Table 1 for further details.)
Wireless motility capsule
The WMC (SmartPill, Medtronic, Minneapolis, MN, USA) consists of a wireless-transmitting, single-use capsule, a portable receiver and display software [18] . (See the ESM for further details.) The regional transit times derived from the electronic data were defined as follows according to the method of Sarosiek et al [19] . Time of capsule ingestion was identified by an abrupt rise in the recorded temperature and a fall in pH (reflecting passage into the acidic environment of the stomach) ( Fig. 1 ) [15] .
Gastric emptying time (GET) was defined as the time between WMC ingestion and the abrupt increase in pH (>2 pH units) caused when the capsule moved through the pylorus from the acidic stomach to the more neutral/alkaline environment of the duodenum.
Small bowel transit time (SBTT) was defined as the time between the end of GET and the passage of the WMC through the ICJ. The ICJ was localised by identifying a sudden fall in pH (>1 pH unit) that followed a gradual and sustained rise in pH through the terminal ileum (pH typically 7-8).
Colonic transit time (CTT) was defined as the time between entry of the WMC into the caecum, defined from the pH drop across the ICJ, to its exit from the body. This was determined in one of two ways: (1) by observing an abrupt fall in temperature followed by a loss of recorded signal after the individual had expelled the WMC, or (2) termination of the datarecording coinciding with a bowel movement recorded in the participant's diary.
WGTT was calculated as the time between capsule ingestion and capsule expulsion.
Study endpoints
The primary endpoint was WGTT. The secondary endpoints were the regional transit times of GET, SBTT and CTT, the magnitude of the pH change across the ICJ and the association of symptoms with questionnaire scores.
Statistical analysis
Data distribution was evaluated using visual inspection of histograms and Shapiro-Wilk testing. Quantitative data are presented either as median with interquartile ranges (IQRs) for non-normally distributed data, or mean ± SD for normally distributed data. For quantitative data, differences between the groups were assessed using the unpaired t test for parametric data and the Mann-Whitney U-test test for non-parametric data. Categorical data were compared using Fisher's exact test. Spearman and Pearson coefficients (r s and r, respectively) are reported dependent on data distribution. Multivariable linear regression was undertaken to assess the association between the primary outcome and total GCSI, adjusted for prespecified potential confounders of disease duration, sex and glycaemic control. p values of <0.05 were adopted as the statistical criterion. Based on previously reported normative data for the primary outcome [15] , a sample size of 41 patients and 41 healthy controls had in excess of 80% power, at a two-sided alpha of 0.05, to detect a difference of 33% in WGTT (WGTT 1932 min ± 637 min) with an SD of 997 min. The statistical analysis was undertaken using proprietary software (STATA, v.12 Stata Corp LP; College Station, TX, USA).
Results
All participants completed the study, although the WMC recording in one patient was unavailable for interpretation because of signal loss during the test. There were no age differences between patients and controls (Table 1) .
Peripheral nerve function
Nerve conduction testing and vibration perception thresholds were obtained for all patients. The main outcome of the nerve conduction tests was the sensory nerve action potential of the median nerve. In comparison to known reference values from healthy participants [20] , the amplitude of the sensory nerve action potential in patients was decreased (median 11 μV, IQR 8-16 μV).
Heart rate variability
All HRV variables were within normal age-specific ranges [21] .
Gastrointestinal transit
In comparison to healthy controls, patients had a significantly prolonged WGTT, GET, SBTT and CTT (Fig. 2, ESM Table 2 ). There was a positive association between vibration perception thresholds and GET and SBTT (r = 0.33, p = 0.02 and r = 0.38, p = 0.01, respectively), but not WGTT. The mean baseline blood glucose was 8.4 mmol/l (range 4.9-12.1 mmol/l). There were no associations between blood glucose concentrations or sensory nerve action potentials and segmental/total transit times. In comparison to published reference values [15] , 21/48 patients (44%) had a single, multisegmental or pan-segmental pathological delay in transit times (see Fig. 3 ).
Gastrointestinal pH profile
In comparison to healthy controls, the magnitude of the pH drop across the ICJ was significantly higher among patients than controls (−1.8 ± 0.4 vs −1.3 ± 0.4; p < 0.0001). In comparison to published reference values [15] , 11/48 patients (23%) had a pathological elevation of drop in pH across the ICJ. Furthermore, the fall in ICJ was positively associated with a prolonged CTT (r s = 0.3, p < 0.001).
Questionnaires PAGI-SYM was completed by all patients. PAGI-SYM provides the subscale nausea, fullness and bloating, and from these scales the total GCSI can be calculated. The mean GCSI was 0.51 ± 0.64 (see ESM Table 2 ). There was an association between WGTT and GCSI when controlling for disease duration, sex and glycaemic control (R 2 = 0.27, p = 0.02, 95% CI 145, 1251 min).
Discussion
In this study, we have demonstrated that, in comparison to an age-matched cohort of healthy controls, patients with type 1 diabetes and established DSPN as a group had pan-enteric prolongation of gastrointestinal transit times. In addition, we found a more profound fall in pH across the ICJ, which may be a surrogate for heightened caecal fermentation, which was associated with a prolonged CTT. These alterations were present in patients without significant gastrointestinal symptoms, although the total GCSI was associated with a prolonged WGTT. To the best of our knowledge, this is the largest study Fig. 1 A typical WMC trace demonstrating temperature (blue line), pH (green line) and contractility (red line). GET is defined as the time from capsule ingestion (CIn) to a sharp rise in pH at the pylorus (Py). SBTT is defined as the time between the reading at the pylorus and the abrupt fall in pH at the ICJ. CTT is defined as the time between the ICJ reading and capsule expulsion (CE), denoted by a rapid fall in temperature as the capsule exits the body. WGTT is derived as the time between CI and CE in the literature to date reporting segmental and pan-enteric transit times in patients with type 1 diabetes using a WMC.
Gastrointestinal motility is regulated and coordinated through a complex bidirectional relationship between the autonomic, central and enteric nervous systems, involving various endocrine and hormonal pathways as well as an interplay with gut microbiota. Despite the fact that the pathogenesis of gastrointestinal dysmotility in diabetes is multifactorial, DAN is a pivotal facet [22] . DAN and DSPN are thought to share a common pathophysiology and therefore frequently coexist in the same patient [23] . This observation is supported by the association, albeit moderate, between vibration perception thresholds and regional transit times. In a previous study by Merio et al, no such association was seen between GET and DSPN, which may reflect differences in patient demographics, duration or severity of disease, as well as the variance in methodologies used to assess and classify the degree and severity of DSPN [22] . In the current study, we found a prolongation of regional and WGTTs in patients with DSPN, potentially indicating the coexistence of DAN in this group, although there was no objective evidence of DAN, as indexed by HRV variables and renal function, in our patient cohort. Interestingly, the time domain analysis of HRV gave lower values in these patients in comparison to age-matched controls, although this was still within the normal range; this suggests that (at least at the point of time when the study was performed) there was no overt evidence of DAN [21] . Nevertheless, disagreement remains over the absolute utility, as well as the interpretation, of HRV variables in diagnosing DAN. However, DAN is not the only factor in the development of gastrointestinal dysmotility as recent data have provided objective support for the emerging role of the enteric nervous system including, but not limited to, enteric neurons and their interconnections, smooth muscle myopathy, changes in macrophage populations in the muscularis, changes in function of the interstitial cells of Cajal and neurotransmission in the development of diabetic enteropathic syndromes [24, 25] .
In agreement with previously reported studies, we found an association between patient-reported symptoms and transit times [26] . Sfarti et al reported that 65% of 69 patients with type 1 diabetes experienced upper abdominal symptoms, but only bloating and upper abdominal pain were significantly associated with a delayed GET [27] . In contrast, Jones et al demonstrated an association between bloating and postprandial fullness with retarded gastric emptying of solids [28] . Taken together, the majority of studies to date have variably identified certain associations between symptoms and segmental transit times, although concordance between studies is limited. A number of factors could potentially explain this variability. For instance, differences in patient selection (type 1 vs type 2 diabetes, duration of disease, glycaemic control, selection bias) and the method by which GET was measured (scintigraphy, breath test, WMC) could account for a proportion of this. Moreover, a plethora of other mechanisms, such as dietary habits, alterations in the microbiota [29] , psychological factors and central nervous system abnormalities, might also contribute to the genesis and maintenance of symptoms, rather than these being caused purely by changes in transit times per se [30] . Neuronal reorganisation within the central nervous system has been demonstrated in diabetes, and more specifically it has been shown that gastrointestinal symptoms are associated with deeper localisation of dipolar sources in the insula-operculum region [3] . Moreover, in diabetes patients with gastrointestinal symptoms, alterations in the following brain areas have been demonstrated: (1) brainstem/operculum/frontal cortex, (2) operculum/cingulate, and (3) mid-cingulate/anterior-cingulate/operculum/deep limbic structures [31] . Gastric emptying scintigraphy is currently considered the gold standard for diagnosing gastroparesis [32] , although the diagnostic accuracy of the WMC has been demonstrated to be comparable [33, 34] . However, other techniques are available to assess GET, such as transabdominal ultrasonography, MRI, radio-opaque markers, the paracetamol absorption test and breath-testing with 13 C-octanoic acid. In comparison to gastric emptying scintigraphy and radio-opaque markers, an advantage of the WMC is that it does not involve ionising radiation. Furthermore, the use of both ultrasonography and MRI is limited by the need to purchase specialised equipment as well as by expertise in interpreting the data [35] . Moreover, scintigraphic and breath-testing methods demand a prolonged clinic/office visit of around 6 h. The WMC additionally offers the opportunity to assess the entire gastrointestinal tract, in terms of both segmental and total transit times and pH patterns, in an ambulatory and relatively minimally invasive manner. However, the absolute relation of the WMC to underlying gastrointestinal motility, due to the indigestible nature of the capsule, coupled with the fact that it is 'free-floating' within the gastrointestinal tract, remains uncertain.
The important clinical implication of our results is the finding of a pan-enteric prolongation of transit times in patients who have hitherto not reported any significant gastrointestinal symptoms, in comparison to healthy control participants. Moreover, nearly half (44%) of such patients have pathologically delayed segmental and/or whole-gut transit. Although prolongation of CTT and WGTT have been previously reported by Sarosiek et al, their study only involved 15 patients with diabetes already known to have gastroparesis [19] . Taken together, these results suggest that pan-enteric alterations in transit are present in patients with diabetes, and therefore testing strategies should not be confined purely to the foregut. Indeed, our results raise the intriguing question of whether type 1 diabetic patients with DSPN should be actively screened for gastrointestinal dysmotility, even in the absence of bothersome symptoms, as demonstrable dysmotility can cause an unpredictable delivery of nutrients to the small bowel and therefore negatively affect glycaemic control and have a potentially deleteriously impact on long-term outcomes [36] .
The patho-aetiology of gastrointestinal dysmotility related to diabetes is incompletely understood, but important 'downstream' consequences are related to alterations in the gut microbiota [37] . Dysfunction within the small bowel is well described in patients with long-standing diabetes, especially in those with coexisting gastroparesis [38] . Camilleri et al reported that small intestinal motility was abnormal in approximately 80% of patients with long-standing diabetes and concomitant delayed GET [39] . This finding leads to the hypothesis that the dysfunction of intestinal motility may predispose to SIBO. Hitherto there has, however, been a paucity of data on whether such SIBO influences colonic sensorimotor function. We, and others, have previously reported that measuring the pH drop across the ICJ may represent a non-invasive biomarker of the quantity of bacterial fermentation in the caecum [17, 29] . Short-chain fatty acids are an end-product of bacterial fermentation and are the major contributor to acidity in this region of the gastrointestinal tract. In patients with functional gastrointestinal disorders, excessive fermentation in the caecum, as putatively indexed by a lower pH across the ICJ, is associated with a reduction in caecal and colonic contractility, as well as symptoms such as bloating and distension [40] . Considering that up to 60% of patients with type 1 diabetes report constipation, this could potentially represent the clinical sequelae of such alterations in the microbiota [38] . The mechanism(s) by which alterations in microbiota, or indeed shortchain fatty acids, contribute to alterations in colonic motility remain incompletely understood. It has been proposed that short-chain fatty acids may act as an intraluminal stimulus, thereby modifying motility patterns within the hindgut [29] . Whether alterations in microbiota are a cause, or indeed an effect, of changes in motility remain to be fully determined. Nevertheless, modulation of gut microbiota in animal models using antibiotics has been demonstrated to improve both insulin signalling and glucose tolerance [41] . Such heightened fermentation in the caecum is, however, a plausible potential therapeutic target by using interventions to alter the composition of the microbiota, which might lead to improvements in colonic motility; this warrants further objective evaluation.
Despite our findings, our study was subject to a number of limitations. First, although we used validated questionnaires to evaluate gastrointestinal symptoms, the interpretation of such relatively crude tools can be influenced by a degree of recall bias, particularly as we did not record symptoms during the WMC test. Second, although the patient and healthy cohorts were well matched from an age perspective, there were more men in the patient cohort; however, we used the previously defined sex-specific transit times in our analysis [15] . Third, the administration of a standardised meal during testing, in this case the SmartBar (Medtronic, Minneapolis, MN, USA), may not represent a typical meal for a patient with diabetes, potentially influencing motility patterns. In addition, we only measured baseline blood glucose rather than using continuous monitoring. Interestingly, we did not observe any associations between baseline blood glucose and segmental or pan-enteric transit times, in contrast to previous studies which have demonstrated that hyperglycaemia slows gastric emptying, while hypoglycaemia profoundly accelerates it [42] . For instance, Russo et al reported that gastric emptying of both solids and liquids is faster during insulin-induced hypoglycaemia in patients with type 1 diabetes, suggesting that gastric motility is an important compensatory mechanism in this context. Fifth, the generalisability of these findings to patients with other types of diabetes, in the absence of neuropathy, remains uncertain. A further point is that the WMC is an indigestible capsule that may not in itself accurately represent transit times and motility under normal physiological conditions. Finally, an inherent limitation of the study is the potential confounding factor of the presence of SIBO and/or lactose intolerance, which we did not objectively test for. In diabetes, impaired intestinal motility can be complicated by SIBO [43, 44] . However, the prevalence of SIBO in patients with diabetes is unclear as there are marked differences dependent on a number of factors including the presence or absence of symptoms, the presence or absence of concomitant DAN and type 1 vs type 2 diabetes [45, 46] . Furthermore, breath-testing for SIBO is also subject to a number of limitations including lack of sensitivity and specificity, choice of carbohydrate substrate used in the test, measurement of other products of fermentation beyond hydrogen and lack of international standardisation in the interpretation of test results [47, 48] . With respect to lactose malabsorption, although we did not specifically test for lactose intolerance, none of the participants reported in their medical history features consistent with this, such as abdominal pain and distension, borborygmi, flatus and/or diarrhoea induced by lactose in dairy products. Self-reported symptoms perform only modestly in excluding lactose intolerance, although the prevalence of lactase persistency, which therefore makes lactose intolerance less likely, is relatively high given the demographics of the study population [49] . However, Rana et al have proposed that there are a number of downstream effects of lactose malabsorption in patients with diabetes, such as lower levels of serum calcium and the presence of osteoporosis, which were not present in our patient cohort, suggesting that this was not a significant confounding factor in our study [50] .
In summary, although recent studies have focused on gastroparesis and symptoms in type 1 diabetes, this study shows a pan-enteric prolongation of transit times prior to the potential development of bothersome symptoms. Thus, treatments that aim to arrest the development and worsening of dysmotility need to be developed. Furthermore, we have demonstrated that patients with prolonged gastrointestinal transit and heightened pH change across the ICJ potentially do not report severe gastrointestinal symptoms. Therefore, it is likely that the current burden of disease is probably underrecognised and underappreciated by clinicians. In conclusion, our finding of delayed transit times and heightened fermentation highlights the need to proactively encourage patients to modify the lifestyle factors such as daily water intake, dietary aspects and physical exercise in order to potentially minimise the consequences of diabetes-induced gut dysmotility. Moreover, recognising patterns of gastrointestinal tract transit abnormalities and alterations in the gastrointestinal pH profile may contribute to our understanding of the pathophysiological mechanisms behind these disorders, which could ultimately lead to the development of new therapies.
